Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below Two Hundred Day Moving Average – Time to Sell?

Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.28 and traded as low as $0.94. Spero Therapeutics shares last traded at $1.03, with a volume of 330,176 shares trading hands.

Analysts Set New Price Targets

A number of research analysts recently issued reports on SPRO shares. Evercore ISI downgraded Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective for the company. in a research note on Friday, December 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research note on Friday, November 15th. TD Cowen restated a “hold” rating on shares of Spero Therapeutics in a research note on Monday, November 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Spero Therapeutics in a report on Monday, December 2nd.

Spero Therapeutics Trading Up 9.1 %

The company has a 50 day simple moving average of $1.17 and a two-hundred day simple moving average of $1.28. The firm has a market capitalization of $56.15 million, a P/E ratio of 14.72 and a beta of 0.59.

Hedge Funds Weigh In On Spero Therapeutics

A hedge fund recently raised its stake in Spero Therapeutics stock. Acadian Asset Management LLC increased its position in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 40.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,071,860 shares of the company’s stock after buying an additional 309,262 shares during the period. Acadian Asset Management LLC owned 1.99% of Spero Therapeutics worth $1,392,000 at the end of the most recent quarter. 25.60% of the stock is currently owned by hedge funds and other institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.